Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Parkinson Disease 4, Autosomal Dominant Lewy Body 4Small Cell Lung Carcinoma 3Carcinoma 3Urothelial Cancer 2Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Recurrence 1Ovarian Neoplasms 1Oligodendroglioma 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Non Small Cell Lung Cancer NSCLC 1Neurocytoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Urothelial Cancer 1Mesothelioma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1

Interventions

selpercatinib 2pembrolizumab 2Cisplatin 2repotrectinib 1pralsetinib 1entrectinib 1Fluorouracil 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Head and Neck Neoplasms × Carboplatin × Clear all
NCT02358031 2025-07-18

MK-3475-048

Merck Sharp & Dohme LLC

Phase 3 Completed
882 enrolled 50 charts 1 FDA
Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡